Adlai Nortye (NASDAQ:ANL) Sees Large Volume Increase – Here’s What Happened

Posted by Stanley Muller on Oct 10th, 2026

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL – Get Free Report) saw an uptick in trading volume on Thursday. 622,510 shares changed hands during trading, an increase of 71% from the previous session’s volume of 363,053 shares. The stock last traded at $14.3780 and had previously closed at $14.05.

Analysts Set New Price Targets

Several equities analysts recently weighed in on ANL shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adlai Nortye in a research note on Tuesday, July 14th. Jefferies Financial Group raised Adlai Nortye to a “strong-buy” rating in a report on Monday, October 5th. Loop Capital set a $49.00 price target on Adlai Nortye in a research note on Tuesday, September 8th. Wall Street Zen upgraded shares of Adlai Nortye from a “hold” rating to a “buy” rating in a research report on Saturday, October 3rd. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Adlai Nortye in a research note on Tuesday, September 8th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Adlai Nortye currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.50.

View Our Latest Stock Analysis on ANL

Adlai Nortye Trading Up 0.7%

The company’s 50 day simple moving average is $14.57 and its 200-day simple moving average is $12.53.

Insider Activity at Adlai Nortye

In other Adlai Nortye news, CFO Xiaofeng Ye sold 5,667 shares of the business’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $14.25, for a total value of $80,754.75. Following the completion of the transaction, the chief financial officer directly owned 147,757 shares in the company, valued at approximately $2,105,537.25. The trade was a 3.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ping Ji sold 10,000 shares of the stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $15.99, for a total value of $159,900.00. Following the transaction, the director directly owned 121,453 shares in the company, valued at approximately $1,942,033.47. This represents a 7.61% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 26,881 shares of company stock valued at $411,060 over the last ninety days.

Institutional Trading of Adlai Nortye

Hedge funds have recently added to or reduced their stakes in the business. Braidwell LP acquired a new position in shares of Adlai Nortye during the 2nd quarter valued at about $9,145,000. Boone Capital Management LLC purchased a new stake in Adlai Nortye in the second quarter valued at approximately $2,971,000. Affinity Asset Advisors LLC acquired a new position in shares of Adlai Nortye in the 1st quarter valued at $1,140,000. ADAR1 Capital Management LLC acquired a new position in shares of Adlai Nortye in the 1st quarter valued at $816,000. Finally, Seven Fleet Capital Management LP purchased a new stake in shares of Adlai Nortye during the 2nd quarter valued at $1,302,000. 35.21% of the stock is owned by institutional investors and hedge funds.

Adlai Nortye Company Profile

(Get Free Report)

Adlai Nortye Ltd. (NASDAQ: ANL) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s research and development programs are centered on immuno-oncology and targeted therapies intended to address unmet medical needs.

Adlai Nortye’s pipeline has included buparlisib, an oral pan-PI3K inhibitor being studied in oncology, as well as AN0025, an investigational EP4 antagonist designed to affect pathways involved in tumor growth and immune response.